Expert NetworkExpert InterviewVKTX

Slingshot members are talking to an expert! The topic is:

Examining the Phase 2 VENTURE-Oral Trial Results for VK2735 in Obesity from Viking Therapeutics

Executed on:Sep 11, 2025 10:00 AM EDT
Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert
Institution: Optum Health
  • Endocrinologist at Optum Sunport Endocrinology in Albuquerque, NM and Assistant Professor of Medicine at the University of New Mexico School of Medicine
  • Manages over 100+ patients with diabetes and obesity
  • Special interest in Lipid and CV Health in patients with diabetes

Interview Goal

The interview aims to explore the positive top-line results from Viking Therapeutics’ Phase 2 VENTURE-Oral trial evaluating VK2735, a once-daily oral dual GLP-1/GIP receptor agonist, in patients with obesity. The discussion will cover the magnitude of weight reduction, the significance of early efficacy signals, safety and tolerability trends, potential for long-term maintenance therapy, and VK2735’s positioning within the evolving obesity treatment landscape.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.